|
 Xywav is currently approved in the United States for the treatment
of excessive daytime sleepiness and sudden loss of muscle tone in
patients aged seven or older with a neurological disorder called
narcolepsy.
Jazz shares rose as much as 1.1% to $146.66 in the afternoon
session.
The U.S. Food and Drug Administration's latest decision allows Xywav
to be used as a treatment for idiopathic hypersomnia, a chronic
sleep disorder with symptoms including excessive daytime sleepiness,
difficulty in waking up and longer nighttime sleep.
Jazz said that it plans to make Xywav available to idiopathic
hypersomnia (IH) patients later this year.
The drug is expected to bring in sales of $1.49 billion by 2025 end,
with $1.1 billion from narcolepsy and around $300 million from IH,
Barclays analyst Balaji Prasad said.
There are an estimated 37,000 diagnosed patients currently in the
United States with idiopathic hypersomnia and there are currently no
approved treatment options for these patients, Jazz Chief Executive
Officer Bruce Cozadd said.
[to top of second column] |
 Jazz has been attempting to
expand its portfolio before the entry of cheaper
generic competition for its top-selling drug
Xyrem no later than 2023. In May, the drugmaker
completed https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-completes-acquisition-gw-pharmaceuticals#:~:text=DUBLIN%20%2C%20May%205%2C%202021%20%2F,of%20cannabinoid-based%20prescription%20medicines
a $7.2 billion acquisition of GW Pharmaceuticals
PLC to add a cannabis-based epilepsy treatment
to its neuroscience business.
Both Xywav and Xyrem carry a boxed warning
flagging risk for potential abuse and misuse and
as a central nervous system depressant.
Earlier this month, Jazz said Xywav brought
sales of $124.2 million and the number of active
Xywav patients grew to 5,100 from 3,900 at the
end of the previous quarter.
(Reporting by Bhanvi Satija and Manojna
Maddipatla in Bengaluru; Editing by Devika
Syamnath and Shailesh Kuber)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
